Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 15, 2021 (6 years ago)

Phenobarbital Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Phenobarbital Tablets, USP 32.4 mg 100 tablets Rx only NdC 13517-111-01 Manufactured for: e5 Pharma, LLC., Boca Raton, FL 33432

Affected NDC 13517-0111-01

Compare with the code on your package — it is the most precise check available.

Drug: Phenobarbital

Recalling firm
Cardinal Health Inc.
NDC code
13517-111-01
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0470-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Phenobarbital recalls

See all
Class III · Low risk

Phenobarbital Elixir

Does Not Meet USP or OTC Monograph: Product exceeds USP specification for alcohol content

Terminated Unapproved drug Monarch PCM, LLC NDC 69367-172-16 D-0878-2022
Class II · Moderate risk

PHENOBARBITAL Sodium Injection

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

Terminated Sterility / contamination Vitae Enim Vitae Scientific, Inc. NDC 42494-416-25 D-0744-2022
Class II · Moderate risk

PHENOBARBITAL Sodium Injection

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

Terminated Sterility / contamination Vitae Enim Vitae Scientific, Inc. NDC 42494-415-25 D-0743-2022
Class II · Moderate risk

Phenobarbital Oral Solution

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1365-2019
Class II · Moderate risk

Phenobarbital Oral Solution

Labeling: Incorrect or Missing Lot and/or Exp Date - the label contains an incorrect Exp Date.

Terminated Labeling / mix-up Lohxa LLC NDC 70166-536-02 D-1131-2019

Other recalls by Cardinal Health Inc.

All 2021 recalls
Class II · Moderate risk

Enoxaparin Sodium Injection

Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL

Ongoing Labeling / mix-up Cardinal Health Inc. NDC 55154-3543-5 D-0597-2025
Class II · Moderate risk

Recombinate

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. D-0573-2025
Class II · Moderate risk

Xolair (omalizumab injection)

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. NDC 50242-214-55 D-0572-2025